Welcome to our dedicated page for NEOGENOMICS SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity award activity. On February 21 and 23, 2026, she converted a total of 29,522 restricted stock units into an equal number of NeoGenomics common shares at no cash exercise price. To cover tax withholding on these vestings, 11,618 common shares were disposed of through share withholding rather than open-market sales. After these transactions, she directly held 93,224 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that continue to vest over time.
NeoGenomics Chief Accounting Officer Greg D. Aunan reported equity compensation activity. On February 21, 2026, he exercised 6,323 restricted stock units, converting them into the same number of shares of common stock at $0.00 per share, reflecting vesting of prior RSU grants. On the same date, 1,875 common shares were withheld and disposed of to cover tax obligations related to the RSU release, rather than an open-market sale. Following these transactions, he directly held 22,027 shares of common stock and maintained multiple outstanding stock option and RSU awards that vest over future anniversaries of their respective grant dates.
NeoGenomics, Inc. is an oncology-focused diagnostics company that runs CAP-accredited and CLIA-certified labs across the U.S. and an ISO-certified lab in Cambridge, U.K. It offers cytogenetics, FISH, flow cytometry, IHC, molecular and NGS panels, MRD testing, morphologic analysis, pharma trial support, and oncology data solutions.
The company serves community oncologists, pathologists, hospitals, reference labs, academic centers, and pharmaceutical sponsors through a single operating segment. Key 2026 priorities include expanding therapy selection and MRD products, deepening its community oncology footprint, improving automation and customer experience, and strengthening culture and cross-functional collaboration.
NeoGenomics operates in a rapidly evolving precision oncology market with growing demand for predictive and MRD testing, but faces intense competition, significant regulatory oversight, reimbursement pressure, data privacy obligations, and operational risks outlined in extensive risk factors.
NeoGenomics, Inc. reported fourth-quarter and full-year 2025 results showing solid revenue growth but continued net losses. Fourth-quarter revenue rose 11% to $190.2 million, with full-year revenue up 10% to $727.3 million, driven by higher test volumes and a shift toward higher value oncology diagnostics.
Fourth-quarter net loss improved to $9.9 million from $15.3 million, while full-year net loss widened to $108.0 million due to items such as impairment and litigation costs. Non-GAAP adjusted EBITDA was positive $13.4 million in Q4 and $43.4 million for 2025, both modestly higher than 2024.
The company highlighted strong growth in next‑generation sequencing, progress on its RaDaR ST minimal residual disease assay, and a successful resolution of RaDaR ST patent litigation. For 2026, NeoGenomics guides revenue to $793–801 million, a smaller GAAP net loss of $50–63 million, and adjusted EBITDA of $55–57 million.
NeoGenomics Inc. President & Chief Operating Officer Stone Warren reported a sale of company stock. On January 20, 2026, he sold 22,128 shares of common stock at a price of $12.5037 per share, leaving him with 121,631 common shares owned directly.
The filing also lists his existing equity awards, including stock options and restricted and performance stock units granted between 2022 and 2025. These include options to buy 166,113 shares at $11.21 exercisable until December 1, 2029, and additional option grants such as 143,266 options and 94,518 options that vest in stages over two years. He also holds sizable restricted stock unit and performance stock unit awards, such as 84,317, 59,382, and 52,687 share-equivalent RSU positions, with vesting tied to continued service and, for performance units, to share price and revenue growth goals. Some options were granted at a premium exercise price set at 110% of the stock’s closing price on specified grant dates.
A holder of NEO common stock has filed a notice under Rule 144 to sell 22,128 shares through Morgan Stanley Smith Barney LLC on the NASDAQ. The filing lists an aggregate market value of about $283,017.12 for the planned sale and identifies that the class of securities is common stock. The notice states that 129,387,801 shares of this class were outstanding at the time of the filing, which serves as a baseline figure, not the amount being sold. The shares to be sold were acquired as restricted stock units from the issuer on January 13, 2026, with the sale expected to occur around January 20, 2026.
NeoGenomics (NEO) President & Chief Operating Officer Warren Stone reported equity activity on January 13, 2026. He acquired 59,382 shares of common stock through the vesting of restricted stock units at an effective price of $0 per share, then disposed of 15,127 shares in a transaction tied to tax withholding obligations. Following these transactions, he directly beneficially owned 143,759 shares of NeoGenomics common stock.
The filing also lists substantial outstanding equity awards, including stock options, restricted stock units, and performance stock units covering multiple future vesting and expiration dates, reflecting a significant portion of his compensation in equity incentives.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity transactions tied to previously granted awards. On January 13, 2026, 59,382 shares of common stock were acquired at $0 per share under transaction code M, reflecting the release of vested restricted stock units. In connection with this vesting, 15,145 shares were disposed of under transaction code F at $0 to cover tax withholding obligations.
Following these transactions, Ms. Olivo directly owned 75,320 shares of NeoGenomics common stock. She also held a range of equity awards, including stock options with various exercise prices and expiration dates, as well as restricted stock units and performance stock units that convert into common stock upon vesting.
NeoGenomics reported select preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025, while emphasizing that these figures are based on management estimates and may change after the year-end audit.
The company also outlined a planned finance leadership transition. Chief Financial Officer Jeffrey S. Sherman notified the board of his intention to retire and will move to Executive Vice President, Finance on March 2, 2026, serve in that role until April 14, 2026, and then act as a special advisor through April 2028. Abhishek Jain has been appointed Executive Vice President, Finance and is expected to become Chief Financial Officer on March 2, 2026. His compensation includes a $520,000 annual base salary, a target annual bonus equal to 60% of salary, and an initial equity award valued at $2,750,000 split evenly between three-year vesting restricted stock units and premium-priced stock options.
NeoGenomics, Inc. reported Q3 2025 results with net revenue of $187.8 million, up from $167.8 million a year ago, as testing volumes and payer mix lifted sales. Gross profit was $80.4 million. The company posted a net loss of $27.1 million (basic and diluted loss per share of $0.21), reflecting higher operating expenses and impairment charges.
Operating loss was $27.0 million, including a $7.1 million impairment tied to a business classified as held for sale. Year to date, net revenue reached $537.2 million and net loss was $98.1 million. Cash and cash equivalents were $164.1 million as of September 30, 2025, after repaying $201.3 million of 2025 convertible notes and $1.3 million of interest in May. Operating cash flow was $3.9 million for the first nine months.
The company closed the Pathline acquisition for $8.5 million; Pathline contributed $4.6 million of revenue in Q3 and recorded a net loss of $2.2 million. Assets held for sale related to Trapelo totaled $2.1 million, and total impairment for the disposal group was $15.3 million year to date. As of October 24, 2025, shares outstanding were 129,387,801.